Related Experiment Video

Updated: Jun 4, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Cost effectiveness of treatments for inflammatory bowel disease

Keith Bodger1

  • 1Department of Gastroenterology, University of Liverpool, Liverpool, UK. kbodger@liverpool.ac.uk

Pharmacoeconomics
|January 29, 2011
PubMed

Insights

The cost-effectiveness of biological therapies for inflammatory bowel diseases (IBD) remains complex. While these treatments offer benefits, their high cost necessitates careful economic evaluation for long-term affordability.

Area of Science:

  • Gastroenterology
  • Health Economics
  • Pharmacoeconomics

Background:

  • Chronic inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), incur significant direct costs, historically dominated by inpatient treatments for severe cases.
  • The introduction of expensive biological agents has shifted the cost burden towards pharmacotherapy, increasing interest in the cost-effectiveness of IBD treatments.
  • Evaluating the affordability of long-term biological therapy is crucial for managing IBD patient care.

Purpose of the Study:

  • To review the existing literature on the cost-effectiveness and affordability of IBD therapies.
  • To identify research gaps and challenges in current cost-effectiveness modeling for IBD treatments.

Main Methods:

  • Literature review of studies assessing the cost-effectiveness of IBD therapies.
  • Analysis of cost-utility models for different treatment strategies in UC and CD.
  • Examination of head-to-head trials and clinical trial data related to cost-effectiveness.

Main Results:

  • Head-to-head trials comparing treatment options are infrequent, and cost-effectiveness is seldom a primary endpoint in clinical trials.
  • Cost-utility models for ulcerative colitis (UC) have explored dosing strategies for 5-aminosalicylic acid (5-ASA) and the impact of adherence.
  • Cost-utility models for Crohn's disease (CD) indicate that anti-tumour necrosis factor (TNF) drugs provide incremental benefits at a higher overall cost, with wide variations in incremental cost-effectiveness ratios.

Conclusions:

  • Existing cost-effectiveness data for IBD therapies, particularly biological agents, are limited and show considerable variability.
  • Challenges and limitations exist in current modeling techniques for assessing the economic value of IBD treatments.
  • Further research is needed to refine cost-effectiveness analyses and inform decisions regarding the long-term affordability of biological therapies for IBD.

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD: